Spider Silk Is Being Tested as Surgical Sutures, Wound Dressings, and Biomedical Protein Material

A dragline silk thread spun by Nephila pilipes, the giant golden orb-weaver found across South and Southeast Asia, has a tensile strength of roughly 1.3 gigapascals, stronger than high-grade steel at a fraction of the weight. That single biological fact is what has made spider silk one of the most studied materials in biomedical engineering over the past two decades. The thread doesn't just resist breaking. It also stretches before it fails, absorbing energy the way no brittle synthetic fibre can, and then it degrades inside the body without triggering the immune cascade that makes many synthetic sutures inflame surrounding tissue.
The protein responsible is called fibroin, a structural protein arranged in tightly packed beta-sheet crystals that give silk its stiffness, surrounded by amorphous regions that give it elasticity. Spiders produce several types of silk from different glands, dragline for the outer frame, capture silk for the sticky spiral, tubuliform silk for egg cases, each tuned to a specific mechanical task. Surgical researchers are most interested in dragline and tubuliform variants because both are strong, both are biocompatible, and both degrade at a pace that can be tuned by adjusting the protein's crystallinity.
The standard synthetic suture materials used in operating theatres today, polyglycolic acid, polylactic acid, nylon, all work, but none of them work quietly. Polyglycolic acid sutures degrade by hydrolysis and release acidic byproducts that cause localised inflammation as they break down. Nylon is non-absorbable and must be removed. Silk sutures have been used in surgery for centuries, but the commercial silk used historically came from silkworms (Bombyx mori), not spiders, and it retained sericin, a coating protein that is immunogenic and caused the chronic reactions that gave silk sutures a poor reputation in the mid-20th century.
Spider silk contains no sericin. Stripped down to pure fibroin, it degrades by protease enzymes already present in tissue, at a rate that matches healing timelines, and the breakdown products are amino acids the body simply absorbs. A 2019 study published in ACS Biomaterials Science and Engineering demonstrated that recombinant spider silk sutures in rat models showed significantly lower inflammatory cell infiltration at 28 days compared to polyglycolic acid controls. The sutures held tensile strength through the critical first two weeks of wound closure and then degraded cleanly.

Spider silk cannot be farmed the way silkworm silk can. Spiders are territorial and cannibalistic; keeping them in density produces fighting and death, not fibre. This is why, despite knowing the material's properties for decades, researchers had no scalable production route until recombinant protein technology caught up.
The current approach involves sequencing the genes that code for spider silk proteins, inserting them into expression systems, yeast, bacteria, transgenic goats, even tobacco plants, and harvesting the protein in bulk before spinning it into fibres. The company Bolt Threads in the United States produced a recombinant silk it called Microsilk using yeast fermentation. Spiber, a Japanese biotech firm, has scaled recombinant silk protein production to commercial volumes and has partnerships with apparel companies, but the same protein is now being evaluated for medical applications. AMSilk in Germany produces recombinant silk proteins specifically for biomedical coatings and suture development.

Spinning recombinant silk protein into a fibre that replicates the mechanical properties of native spider silk remains technically difficult. Native silk is spun through a spinneret under precise pH and ion-concentration gradients that trigger the protein to self-assemble. Laboratory spinning processes approximate this but do not fully replicate it, which means current recombinant silk fibres are strong but not yet as strong as what the spider produces. The gap is narrowing.
Silk's biomedical application extends beyond sutures into wound dressings, and here the material has a property that sutures don't require but dressings desperately need: it can be processed into films, sponges, and hydrogels that maintain a moist wound environment while remaining permeable to oxygen. Chronic wounds, diabetic foot ulcers, pressure sores, heal faster in moist environments, but moisture also creates conditions for bacterial colonisation.

Fibroin-based dressings address this partly through the material's own structure. A 2021 paper in Acta Biomaterialia showed that electrospun silk fibroin nanofibre mats supported keratinocyte migration, the cell movement that closes a wound surface, at rates significantly higher than standard gauze controls, while the nanoscale fibre architecture physically inhibited bacterial adhesion. Researchers are also loading silk hydrogels with antimicrobial peptides and growth factors, using the silk matrix as a slow-release vehicle. The protein degrades gradually, releasing its payload in step with the healing process rather than in a single burst.
In India, where diabetic wound care is a significant clinical burden, the International Diabetes Federation estimated India had over 77 million people with diabetes as of its 2021 atlas, a low-cost, biocompatible dressing that reduces infection and accelerates closure would have direct public health relevance. Several Indian research groups, including teams at IIT Bombay and the National Institute of Animal Biotechnology in Hyderabad, have published work on silk-based wound care scaffolds using both Bombyx mori fibroin and recombinant spider silk proteins.
The same properties that make spider silk useful inside a wound, high tensile strength, elasticity, light weight, and the ability to absorb impact energy before failure, make it interesting for protective materials outside the body. Ballistic protection, cut-resistant gloves, and flexible body armour are the applications most frequently cited, and the comparison to Kevlar is standard: spider silk has a toughness (the area under the stress-strain curve, combining strength and elasticity) that exceeds Kevlar by a significant margin, though Kevlar remains easier and cheaper to produce at scale.
The more immediate protective application is in medical device coatings. Implants, hip replacements, stents, cochlear implants, fail partly because the body recognises the foreign surface and walls it off with fibrous tissue. Coating implant surfaces with silk fibroin reduces this foreign body response. The protein presents a surface chemistry that immune cells read as biological rather than synthetic, reducing the fibrous capsule that forms around silicone breast implants and the inflammatory sheath that can form around pacemaker leads.
What spider silk research is converging on is not a single product but a design principle: a material that interacts with biological systems on biological terms, degrades on a schedule set by the body's own enzymes, and carries mechanical properties that synthetic polymers have spent decades trying to approximate. The suture and the wound dressing are early applications. The implant coating and the impact-absorbing body armour are the same protein, asked different questions.